Aflibercept is a fusion protein designed to inhibit VEGF-A and placental growth factor (PIGF). Based on promising results from the phase 2 DaVINCI studies, the VIVID and VISTA DME studies were initiated and served as the pivotal phase 3 trials used as the basis for global regulatory submissions.
Quiz Module 10.11
To validate your answers and keep track of your progress please sign in or register a new account
1. Aflibercept is designed to inhibit VEGF-A and placental growth factor (PIGF) with what kind of agent?
2. The study results showed that both arms had significant BCVA improvements at 1 year when compared to: